NetScientific PLC (GB:EMVC)
LSE:EMVC
Top Page
NetScientific
(LSE:EMVC)
Select Model
Select Model
Rating:52Neutral
Price Target:
58.00 p
▼(-4.13% Downside)
Action:ReiteratedDate:12/07/25
The overall stock score is primarily influenced by the company's financial performance challenges, particularly in profitability and cash flow management. While technical indicators show bullish momentum, the valuation is unattractive due to negative earnings. Positive corporate events provide some optimism for future growth and strategic positioning.
Positive Factors
Revenue Growth
Strong revenue growth indicates potential for market expansion and increased demand for NetScientific's portfolio companies' innovations.
Negative Factors
Profitability Challenges
Ongoing profitability challenges can hinder sustainable growth and shareholder value, requiring strategic improvements in cost management.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong revenue growth indicates potential for market expansion and increased demand for NetScientific's portfolio companies' innovations.
Read all positive factors
NetScientific (EMVC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£14.40M
Dividend YieldN/A
Average Volume (3M)31.99K
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue Growth30.40%
EPS Growth23.48%
CountryUK
Employees29
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)N/A
Shares Outstanding27,967,531
10 Day Avg. Volume35,929
30 Day Avg. Volume31,987
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)0.78
Price to Sales (P/S)4.82
P/FCF Ratio-5.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)£3.42M
NetScientific Business Overview & Revenue Model
Company Description
EMV Capital plc is a venture capital firm specializing in seed, growth capital, early and mid stage investments. The firm focuses to invest in sustainability, life science, technology, transformative biomedical, deep tech, semiconductors, industri...
How the Company Makes Money
NetScientific generates revenue primarily through its investments in a diverse portfolio of life sciences companies. The company makes money by taking equity stakes in these firms, which can lead to significant returns upon successful exits throug...
NetScientific Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.36M | 2.45M | 1.45M | 1.00M | 1.11M | 394.00K |
| Gross Profit | 1.75M | 2.09M | 1.23M | 782.00K | 989.00K | 348.00K |
| EBITDA | -2.74M | -3.12M | -2.27M | -3.31M | -2.65M | -2.20M |
| Net Income | -2.50M | -3.06M | -2.64M | -3.09M | -2.38M | -1.61M |
Balance Sheet | ||||||
| Total Assets | 19.65M | 19.50M | 22.46M | 28.95M | 20.69M | 8.07M |
| Cash, Cash Equivalents and Short-Term Investments | 548.00K | 949.00K | 347.00K | 580.00K | 2.35M | 1.03M |
| Total Debt | 1.49M | 1.53M | 2.53M | 1.25M | 654.00K | 509.00K |
| Total Liabilities | 6.07M | 5.43M | 5.35M | 3.71M | 2.18M | 1.17M |
| Stockholders Equity | 14.82M | 15.10M | 17.83M | 25.84M | 18.50M | 6.74M |
Cash Flow | ||||||
| Free Cash Flow | -1.45M | -1.97M | -3.51M | -3.16M | -3.54M | -2.88M |
| Operating Cash Flow | -1.44M | -1.78M | -3.14M | -2.56M | -3.48M | -2.79M |
| Investing Cash Flow | 140.00K | 12.00K | 1.11M | -1.08M | -3.46M | -959.00K |
| Financing Cash Flow | 1.52M | 2.57M | 1.39M | 1.74M | 8.02M | 1.89M |
NetScientific Technical Analysis
Negative
60.50
Price Trends
55.52
Negative
55.34
Negative
51.35
Positive
Market Momentum
-1.35
Positive
15.72
Positive
29.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EMVC, the sentiment is Negative. The current price of 60.5 is above the 20-day moving average (MA) of 54.38, above the 50-day MA of 55.52, and above the 200-day MA of 51.35, indicating a neutral trend. The MACD of -1.35 indicates Positive momentum. The RSI at 15.72 is Positive, neither overbought nor oversold. The STOCH value of 29.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:EMVC.
NetScientific Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
62 Neutral | £18.46M | ― | 16.48% | ― | -79.36% | 78.16% | |
52 Neutral | £14.40M | -2.82 | -16.69% | ― | 30.40% | 23.48% | |
48 Neutral | £20.76M | -2.00 | 74.44% | ― | 15.59% | 54.47% | |
44 Neutral | £14.09M | -19.81 | -21.85% | ― | ― | ― | |
43 Neutral | £8.13M | -2.08 | -14.62% | ― | -9.22% | -386.93% | |
42 Neutral | £19.20M | -2.92 | -36.43% | ― | 59.01% | -164.94% |
* Financial Sector Average
GB:EMVC
NetScientific
51.50
12.50
32.05%
GB:FIPP
Frontier IP
10.75
-11.25
-51.14%
GB:MAFL
Mineral & Financial Investments
47.50
25.50
115.91%
GB:KRM
KRM22
35.00
8.50
32.08%
GB:450
Marwyn Acquisition Company PLC
2.10
0.00
0.00%
GB:TEAM
TEAM plc
17.50
5.00
40.00%
NetScientific Corporate Events
Regulatory Filings and Compliance
EMV Capital Discloses PDMR Share Transfer with No Change in Beneficial Holding
Neutral
Jan 8, 2026
EMV Capital plc has disclosed a transaction by person discharging managerial responsibilities (PDMR) Nick Salisbury, who transferred 7,000 ordinary shares from his personal brokerage account to his Self-Invested Personal Pension for portfolio cons...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
EMV Capital-backed Sofant Secures £6.25m to Pivot from R&D to Commercial Rollout
Positive
Dec 23, 2025
EMV Capital’s portfolio company Sofant Technologies has raised around £6.25m in a pivotal equity round that converts the bulk of its outstanding loans into shares and injects new capital to fund the shift from multi-year RD to commercia...
Regulatory Filings and Compliance
EMV Capital Discloses Director’s Internal Share Transfer With Holding Unchanged
Neutral
Dec 19, 2025
EMV Capital plc reported an internal share transfer by Senior Independent Director Jonathan Robinson, who moved 34,484 ordinary shares from his personal brokerage account into his Self-Invested Personal Pension for portfolio consolidation via a sa...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Wanda Health Secures £0.86 Million to Boost US Expansion
Positive
Dec 10, 2025
Wanda Health, a portfolio company of EMV Capital, has successfully raised £0.86 million to accelerate its operations and product development in the US healthcare market. The fundraising, led by EMV Capital Partners, will help Wanda scale its ...
Business Operations and StrategyPrivate Placements and Financing
EMV Capital Issues New Shares to Directors, Boosting Market Confidence
Positive
Dec 8, 2025
EMV Capital plc has announced the issuance of 200,141 new ordinary shares to its directors and a PDMR in lieu of cash bonuses and fees, priced at £0.55 per share. This move reflects a strategic decision to align management interests with comp...
Business Operations and StrategyExecutive/Board Changes
EMV Capital Expands Finance Leadership to Support Growth
Positive
Nov 24, 2025
EMV Capital plc has announced a significant expansion of its senior finance leadership team, appointing Anesh Patel as the new Group Chief Financial Officer and transitioning Stephen Crowe to the newly created role of Portfolio CFO. This strategic...
Business Operations and Strategy
EMV Capital to Host Virtual Portfolio Showcase
Positive
Nov 20, 2025
EMV Capital plc announced a virtual ‘Meet the Portfolio’ event on December 1, 2025, to provide investors insights into its portfolio companies, Wanda Health and DeepTech Recycling. This event, part of EMV Capital’s ongoing invest...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.